Evidence map›Paper›PMID 38965434›Full record

Trial reportNature medicine2024

Extension of efficacy range for targeted malaria-elimination interventions due to spillover effects.

Jade Benjamin-Chung, Haodong Li, Anna Nguyen, Gabriella Barratt Heitmann, Adam Bennett, Henry Ntuku, Lisa M Prach, Munyaradzi Tambo, Lindsey Wu, Chris Drakeley and 7 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jade Benjamin-ChungDepartment of Epidemiology and Population Health, Stanford University, Stanford, CA, USA. jadebc@stanford.edu.ORCID http://orcid.org/0000-0003-3631-3132
Haodong LiDivision of Biostatistics, University of California, Berkeley, Berkeley, CA, USA.
Anna NguyenDepartment of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.
Gabriella Barratt HeitmannDepartment of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.
Adam BennettMalaria Elimination Initiative, Global Health Group, University of California, San Francisco, San Francisco, CA, USA.
Henry NtukuMalaria Elimination Initiative, Global Health Group, University of California, San Francisco, San Francisco, CA, USA.
Lisa M PrachMalaria Elimination Initiative, Global Health Group, University of California, San Francisco, San Francisco, CA, USA.
Munyaradzi TamboMultidisciplinary Research Centre, University of Namibia, Windhoek, Namibia.
Lindsey WuDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
Chris DrakeleyDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0003-4863-075X
Roly GoslingMalaria Elimination Initiative, Global Health Group, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6291-0024
Davis MumbengegwiUniversity of Namibia, Windhoek, Namibia.
Immo KleinschmidtMRC International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0002-2422-9008
Jennifer L SmithMalaria Elimination Initiative, Global Health Group, University of California, San Francisco, San Francisco, CA, USA.
Alan HubbardDivision of Biostatistics, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-3769-0127
Mark van der LaanDivision of Biostatistics, University of California, Berkeley, Berkeley, CA, USA.
Michelle S HsiangChan Zuckerberg Biohub, San Francisco, CA, USA.

Funding

Stanford BSSR Pre-Doctoral Training Program at the Intersection of Data Sciences with Behavioral, Social, and Population Health ResearchT32HL151323 · NHLBI · STANFORD UNIVERSITY · PI Michelle Christina Odden, David H Rehkopf · 2020 to 2026
$1.6M
Genetic and social network analysis to target interventions for malaria eliminationK01AI153555 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SMITH, JENNIFER LINNEA · 2020 to 2024
$725k
Measuring spillover effects of reactive, focal malaria elimination interventionsK01AI141616 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI BENJAMIN-CHUNG, JADE · 2019 to 2022
$601k
NHLBI NIH HHS T32 HL151323NIAID NIH HHS K01 AI141616NIAID NIH HHS K01 AI153555Novartis Foundation A122666U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) T32HL151323U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K01AI141616
6 · The paper itself

Abstract

Malaria-elimination interventions aim to extinguish hotspots and prevent transmission to nearby areas. Here, we re-analyzed a cluster-randomized trial of reactive, focal interventions (chemoprevention using artemether-lumefantrine and/or indoor residual spraying with pirimiphos-methyl) delivered within 500 m of confirmed malaria index cases in Namibia to measure direct effects (among intervention recipients within 500 m) and spillover effects (among non-intervention recipients within 3 km) on incidence, prevalence and seroprevalence. There was no or weak evidence of direct effects, but the sample size of intervention recipients was small, limiting statistical power. There was the strongest evidence of spillover effects of combined chemoprevention and indoor residual spraying. Among non-recipients within 1 km of index cases, the combined intervention reduced malaria incidence by 43% (95% confidence interval, 20-59%). In analyses among non-recipients within 3 km of interventions, the combined intervention reduced infection prevalence by 79% (6-95%) and seroprevalence, which captures recent infections and has higher statistical power, by 34% (20-45%). Accounting for spillover effects increased the cost-effectiveness of the combined intervention by 42%. Targeting hotspots with combined chemoprevention and vector-control interventions can indirectly benefit non-recipients up to 3 km away.

Indexed as

MalariaAnimalsAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChemopreventionChildChild, PreschoolDisease EradicationDrug CombinationsEthanolaminesFemaleFluorenesHumansIncidenceInsecticidesAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsEthanolaminesFluorenesInsecticidesOrganothiophosphorus Compoundspirimiphos methyl

Identifiers

PMID38965434
PMCPMC11483210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.